{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:48:34Z","timestamp":1790642914934,"version":"4.1.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UF Foundation Gatorade fund"},{"name":"Forefront Biomed International fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.critrevonc.2015.06.006","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T11:03:05Z","timestamp":1435834985000},"page":"399-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Immunotherapy for multiple myeloma: Current status and future directions"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-7877","authenticated-orcid":false,"given":"Ayed O.","family":"Ayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung-Ji","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan S.","family":"Moreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.06.006_bib0120","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","article-title":"T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect","volume":"98","author":"Alyea","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0600","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/leu.2013.310","article-title":"Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma","volume":"28","author":"Atanackovic","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0305","first-page":"4516","article-title":"Human CD4+ CD25+ regulatory T cells suppress NKT cell functions","volume":"63","author":"Azuma","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0770","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/gt.2010.174","article-title":"Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells","volume":"18","author":"Barber","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0705","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/ITT.S30818","article-title":"Update on the challenges and recent advances in cancer immunotherapy","volume":"2","author":"Baronzio","year":"2013","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2012.09251.x","article-title":"A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma","volume":"159","author":"Bensinger","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0605","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0625","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1182\/blood-2011-06-360255","article-title":"IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect","volume":"118","author":"Benson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0630","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1182\/blood-2012-06-438028","article-title":"A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Benson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0475","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2741\/4202","article-title":"Lorvotuzumab mertansine: antibody-drug-conjugate for CD56(+) multiple myeloma","volume":"19","author":"Berdeja","year":"2014","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0615","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0050","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up","volume":"29","author":"Bjorkstrand","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0650","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00277-013-1924-9","article-title":"BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma","volume":"93","author":"Bolkun","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0280","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.clim.2010.04.019","article-title":"Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide","volume":"136","author":"Bontkes","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0735","doi-asserted-by":"crossref","first-page":"293479","DOI":"10.1155\/2012\/293479","article-title":"The role of regulatory T cells and TH17 cells in multiple myeloma","volume":"2012","author":"Braga","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0195","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2012-02-410373","article-title":"CARs and cancers: questions and answers","volume":"119","author":"Brentjens","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0055","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0565","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000354194","article-title":"Impact of interleukin-6 in hematological malignancies","volume":"40","author":"Burger","year":"2013","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0480","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-04-0182","article-title":"CD74 is expressed by multiple myeloma and is a promising target for therapy","volume":"10","author":"Burton","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0240","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0620","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"Natural killer cell biology: an update and future directions","volume":"132","author":"Campbell","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0245","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0160","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0215","series-title":"Proceedings of the 105th Annual Meeting of the American Association for Cancer Research","article-title":"Engineering multiple chimeric antigen receptors in T cells for the treatment of multiple myeloma","author":"Chang","year":"2014"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0230","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.it.2003.10.012","article-title":"NK cell and DC interactions","volume":"25","author":"Cooper","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0125","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0380","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0150","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0025","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3109\/10428194.2010.487959","article-title":"Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches","volume":"51","author":"Engelhardt","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0180","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PPO.0000000000000040","article-title":"Novel approaches to enhance the specificity and safety of engineered T cells","volume":"20","author":"Fedorov","year":"2014","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0730","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","article-title":"CD4(+) CD25(+) FoxP3 (+) regulatory T cells are increased whilst CD3 (+) CD4 (\u2212) CD8 (\u2212) alpha beta TCR (+) double negative t cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden","volume":"144","author":"Feyler","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0555","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(05)70287-4","article-title":"Identification of CD162 in plasma-cell dyscrasia","volume":"6","author":"Florena","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0655","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00277-012-1470-x","article-title":"B cell-activating factor: its clinical significance in multiple myeloma patients","volume":"91","author":"Fragioudaki","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0765","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.4049\/jimmunol.1101202","article-title":"Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+ CD4+ T cells: evidence from myeloma-bearing mouse model","volume":"187","author":"Freeman","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0265","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0035","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma, European Group for Bone Marrow Transplantation","volume":"325","author":"Gahrton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0060","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0040","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/bmt.2013.54","article-title":"Cellular immunotherapy for plasma cell myeloma","volume":"48","author":"Garfall","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0270","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3324\/haematol.2011.056747","article-title":"Highly activated and expanded natural killer cells for multiple myeloma immunotherapy","volume":"97","author":"Garg","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0740","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.2011.575","article-title":"The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma","volume":"106","author":"Giannopoulos","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0220","first-page":"21","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Gienke","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0640","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","article-title":"Targeting angiogenesis: progress with anti-VEGF treatment with large molecules","volume":"6","author":"Grothey","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0145","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0695","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.mt.6300138","article-title":"Recent advances and current challenges in tumor immunology and immunotherapy","volume":"15","author":"Guinn","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0715","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.mt.6300369","article-title":"Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells","volume":"16","author":"Han","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-6-47","article-title":"Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges","volume":"6","author":"Han","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0510","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1126\/science.290.5497.1768","article-title":"Down-regulation of the macrophage lineage through interaction with OX2 (CD200)","volume":"290","author":"Hoek","year":"2000","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.critrevonc.2015.06.006_bib0775","doi-asserted-by":"crossref","first-page":"e51892","DOI":"10.1371\/journal.pone.0051892","article-title":"A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease","volume":"7","author":"Hofgaard","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0435","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2010-01-265280","article-title":"Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies","volume":"116","author":"Horton","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0570","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2010.08533.x","article-title":"Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma","volume":"152","author":"Hunsucker","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0420","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","article-title":"A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma","volume":"95","author":"Hussein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0455","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0610","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0365","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0155","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0225","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0520","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2141.2008.07024.x","article-title":"Anti-CD20 monoclonal antibody therapy in multiple myeloma","volume":"141","author":"Kapoor","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0275","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ajh.22163","article-title":"Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells","volume":"86","author":"Katodritou","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0490","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.12565","article-title":"Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma","volume":"163","author":"Kaufman","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0595","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0460","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1182\/blood.V124.21.4736.4736","article-title":"Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib","volume":"124","author":"Kelly","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.bmt.1705033","article-title":"Reversal of severe graft-versus-host disease after nonmyeloablative matched unrelated donor stem cell transplant by infusion of backup autologous peripheral blood stem cells","volume":"36","author":"Khan","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0235","doi-asserted-by":"crossref","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0690","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0110","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","article-title":"Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma","volume":"37","author":"Kroger","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0635","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2403084","article-title":"Expression of VEGF and its receptors by myeloma cells","volume":"17","author":"Kumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0580","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0445","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/leu.2011.290","article-title":"Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells","volume":"26","author":"Lamorte","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0250","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.4049\/jimmunol.172.12.7335","article-title":"Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients","volume":"172","author":"Lee","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0325","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.12943","article-title":"Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma","volume":"166","author":"Li","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0535","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2003-12-4331","article-title":"Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency","volume":"103","author":"Lim","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0190","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00262-012-1254-0","article-title":"Targeted immunotherapy of cancer with CAR T cells: achievements and challenges","volume":"61","author":"Lipowska-Bhalla","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0080","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0045","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0360","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0400","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V124.21.83.83","article-title":"A phase Ib dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma","volume":"124","author":"Martin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0200","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0505","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00404426","article-title":"Characterization of the human homolog of the rat MRC OX-2 membrane glycoprotein","volume":"25","author":"McCaughan","year":"1987","journal-title":"Immunogenetics"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0115","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood.V100.9.3128","article-title":"Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study","volume":"100","author":"Mohty","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bmt.1704756","article-title":"Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC)","volume":"35","author":"Mohty","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0525","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.leu.2404558","article-title":"Rituximab in CD20 positive multiple myeloma","volume":"21","author":"Moreau","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0395","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.V124.21.176.176","article-title":"An open-label, multicenter phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma","volume":"124","author":"Moreau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0515","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0745","doi-asserted-by":"crossref","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0665","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0295","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.leukres.2011.03.032","article-title":"Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma","volume":"35","author":"Nguyen-Pham","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12307-011-0086-3","article-title":"The immune microenvironment of myeloma","volume":"4","author":"Noonan","year":"2011","journal-title":"Cancer Microenviron."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.06.006_bib0780","doi-asserted-by":"crossref","first-page":"e65075","DOI":"10.1371\/journal.pone.0065075","article-title":"Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model","volume":"8","author":"Nur","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0385","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0440","first-page":"177","article-title":"CD138 (syndecan-1) expression in health and disease","volume":"29","author":"Palaiologou","year":"2014","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","article-title":"Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity","volume":"9","author":"Peggs","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0390","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V124.21.84.84","article-title":"Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed refractory multiple myeloma","volume":"124","author":"Plesner","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0140","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s002620100192","article-title":"Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector","volume":"50","author":"Power","year":"2001","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0725","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0760","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2011-07-368472","article-title":"Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma","volume":"119","author":"Qian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0130","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-09-0418","article-title":"Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells","volume":"15","author":"Rapoport","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0135","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2010-08-299396","article-title":"Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma","volume":"117","author":"Rapoport","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.06.006_bib0330","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2011.08790.x","article-title":"Monoclonal antibodies in the treatment of multiple myeloma","volume":"154","author":"Richardson","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0315","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0070","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0590","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.bmt.1705138","article-title":"Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140mg\/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects","volume":"36","author":"Rossi","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0675","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.bjc.6605241","article-title":"Atacicept in relapsed\/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study","volume":"101","author":"Rossi","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0255","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0750","doi-asserted-by":"crossref","first-page":"196063","DOI":"10.1155\/2012\/196063","article-title":"Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes","volume":"2012","author":"Rutella","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0085","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bmt.1702685","article-title":"Donor leukocyte infusions for multiple myeloma","volume":"26","author":"Salama","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0495","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-05-0204","article-title":"Anti-CD74 antibody\u2013doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys","volume":"11","author":"Sapra","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0310","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1940-6207.CAPR-10-0138","article-title":"Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model","volume":"3","author":"Sharabi","year":"2010","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0260","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","article-title":"Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation","volume":"143","author":"Shi","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0005","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0645","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2141.2011.08623.x","article-title":"Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed\/refractory multiple myeloma: a California Cancer Consortium trial","volume":"154","author":"Somlo","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0285","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1158\/1078-0432.CCR-07-5290","article-title":"Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy","volume":"14","author":"Song","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0485","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: a new candidate target for the immunotherapy of B-cell neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0500","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1158\/1078-0432.CCR-08-1953","article-title":"Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines","volume":"15","author":"Stein","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0375","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V77.5.1071.1071","article-title":"Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody","volume":"77","author":"Stevenson","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0685","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0340","doi-asserted-by":"crossref","first-page":"924058","DOI":"10.1155\/2011\/924058","article-title":"Antibody-based therapies in multiple myeloma","volume":"2011","author":"Tai","year":"2011","journal-title":"Bone Marrow Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0405","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.V99.4.1419","article-title":"CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells","volume":"99","author":"Tai","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0415","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/0008-5472.CAN-03-3630","article-title":"Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications","volume":"64","author":"Tai","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0425","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1158\/0008-5472.CAN-05-1657","article-title":"Immunomodulatory drug lenalidomide (CC-5013IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications","volume":"65","author":"Tai","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0660","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0350","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0345","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1182\/blood-2008-10-183772","article-title":"CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells","volume":"113","author":"Tai","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0470","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-04-0142","article-title":"In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2\u2032-deacetyl-N2\u2032-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells","volume":"64","author":"Tassone","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0755","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0540","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","article-title":"CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications","volume":"25","author":"Treon","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0560","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2174\/156800909789056971","article-title":"P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma","volume":"9","author":"Tripodo","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0465","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V76.2.377.377","article-title":"Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19)","volume":"76","author":"Van Camp","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0335","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/leu.2011.214","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"van de Donk","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0165","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","article-title":"T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells","volume":"108","author":"Vera","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0575","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2009.07647.x","article-title":"Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death","volume":"145","author":"Voorhees","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0585","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0680","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nm0303-269","article-title":"Immunotherapy: past, present and future","volume":"9","author":"Waldmann","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0410","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.152.1.117","article-title":"CD40 expression in malignant plasma cells, Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line","volume":"152","author":"Westendorf","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0450","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10428199809057596","article-title":"Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia","volume":"31","author":"Witzig","year":"1998","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0670","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.leu.2405048","article-title":"Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts","volume":"22","author":"Yaccoby","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0545","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2006.08.025","article-title":"Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies","volume":"10","author":"Yang","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0710","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PPO.0b013e3181c51f0d","article-title":"Novel immunotherapies","volume":"15","author":"Yi","year":"2009","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0700","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/eji.201190035","article-title":"Cancer immunotherapy: progress and challenges in the clinical setting","volume":"41","author":"Zarour","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0320","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.18632\/oncotarget.1584","article-title":"Heat shock proteins in multiple myeloma","volume":"5","author":"Zhang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0550","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ijc.28745","article-title":"Anti-\u03b22M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity","volume":"135","author":"Zhang","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0300","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1365-2141.2002.03712.x","article-title":"Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma","volume":"118","author":"Zheng","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0210","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","article-title":"Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0530","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/10428190600564803","article-title":"Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma","volume":"47","author":"Zojer","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.06.006_bib0355","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815001249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815001249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T23:20:31Z","timestamp":1691796031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815001249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":155,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1040842815001249"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.06.006","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for multiple myeloma: Current status and future directions","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}